These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38009232)

  • 1. Molecular imaging of PARP in cancer: state-of-the-art.
    Filippi L; Urso L; Frantellizzi V; Marzo K; Marzola MC; Schillaci O; Evangelista L
    Expert Rev Mol Diagn; 2023; 23(12):1167-1174. PubMed ID: 38009232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study.
    Pantel AR; Gitto SB; Makvandi M; Kim H; Medvedv S; Weeks JK; Torigian DA; Hsieh CJ; Ferman B; Latif NA; Tanyi JL; Martin LP; Lanzo SM; Liu F; Cao Q; Mills GB; Doot RK; Mankoff DA; Mach RH; Lin LL; Simpkins F
    Clin Cancer Res; 2023 Apr; 29(8):1515-1527. PubMed ID: 36441795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo visualization of PARP inhibitor pharmacodynamics.
    McDonald ES; Pantel AR; Shah PD; Farwell MD; Clark AS; Doot RK; Pryma DA; Carlin SD
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Development of
    Lee HS; Schwarz SW; Schubert EK; Chen DL; Doot RK; Makvandi M; Lin LL; McDonald ES; Mankoff DA; Mach RH
    Radiol Imaging Cancer; 2022 Jan; 4(1):e210070. PubMed ID: 35089089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
    Dehdashti F; Reimers MA; Shoghi KI; Chen DL; Luo J; Rogers B; Pachynski RK; Sreekumar S; Weimholt C; Zhou D
    Mol Imaging Biol; 2022 Dec; 24(6):853-861. PubMed ID: 35701722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamic Activity of [
    Lin LL; Wong F; Lin R; Yap T; Litton JK
    JCO Precis Oncol; 2024 Aug; 8():e2400303. PubMed ID: 39208372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted
    Young AJ; Pantel AR; Viswanath V; Dominguez TL; Makvandi M; Lee H; Li S; Schubert EK; Pryma DA; Farwell MD; Mach RH; Simpkins F; Lin LL; Mankoff DA; Doot RK
    J Nucl Med; 2022 Jan; 63(1):44-50. PubMed ID: 33863820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, Synthesis, and Evaluation of [
    Zheng W; Huang Y; Xie Y; Yang T; Cheng X; Chen H; Li C; Jiang Z; Yu Z; Li Z; Zhang L; Yuan L; Liu Y; Liang Y; Wu Z
    Mol Pharm; 2024 May; 21(5):2606-2621. PubMed ID: 38606716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors.
    Chu YY; Yam C; Yamaguchi H; Hung MC
    J Biomed Sci; 2022 Oct; 29(1):86. PubMed ID: 36284291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The evolving landscape of predictive biomarkers of response to PARP inhibitors.
    Thomas A; Murai J; Pommier Y
    J Clin Invest; 2018 May; 128(5):1727-1730. PubMed ID: 29664016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of PARP Inhibitor Resistance.
    O'Connor MJ; Forment JV
    Cancer Treat Res; 2023; 186():25-42. PubMed ID: 37978129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence.
    Bieńkowski M; Tomasik B; Braun M; Jassem J
    Cancer Treat Rev; 2022 Mar; 104():102359. PubMed ID: 35190335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
    Lee EK; Matulonis UA
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):165-188. PubMed ID: 32569489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two experts and a newbie: [
    Stotz S; Kinzler J; Nies AT; Schwab M; Maurer A
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):834-846. PubMed ID: 34486071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitor resistance mechanisms and PARP inhibitor derived imaging probes.
    Yu T; Lok BH
    Expert Rev Anticancer Ther; 2024 Oct; 24(10):989-1008. PubMed ID: 39199000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    Papa A; Caruso D; Strudel M; Tomao S; Tomao F
    J Transl Med; 2016 Sep; 14():267. PubMed ID: 27634150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid phase radiosynthesis of an olaparib derivative using 4-[
    Xu J; Chen H; Rogers BE; Katzenellenbogen JA; Zhou D
    Nucl Med Biol; 2022; 114-115():65-70. PubMed ID: 36193598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.